Knee Replacement Prosthesis Companies and Corporate Growth

Major Companies Role in the Knee Replacement Prosthesis Market

• ConforMIS, Inc.
• JRI Orthopaedics Ltd.
• Medacta International SA
• United Orthopedic Corporation
• MicroPort Scientific Corporation
• Zimmerer GmbH
• DJO Global Inc.
• Stryker Corporation
• Arthrex, Inc.
• Johnson & Johnson (DePuy Synthes)
• B. Braun Melsungen AG
• Corin Group PLC
• Waldemar Link GmbH & Co. KG
• Exactech Inc.
• Smith & Nephew plc
• LimaCorporate S.p.A.
• Japan MDM, Inc.
• Zimmer Biomet Holdings, Inc.
• Mathys AG Bettlach
• Ortosintese

Market Growth

The global knee replacement prosthesis market was estimated at US$ 12.1 billion in 2023 and is projected to grow to US$ 22.73 billion by 2034, rising at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2034.

Knee Replacement Prosthesis Market Trends

• In April 2025, OSSTEC announced that it raised £2.5 million in funding to launch its implant in the market and scale its impact with strategic partners in the medical field. The London-based firm aims to change the face of joint replacement implants with a novel 3D printing technology.
• In August 2024, Alkem MedTech announced a collaboration with Exactech, Inc. to manufacture and market its joint replacement implants in India. The partnership was made to grant Alkem MedTech access to the design, manufacturing expertise, and marketing rights of Exactech’s brands.
• In August 2024, according to Alkem Laboratories, its subsidiary teamed up with Exactech Inc., a US-based company, to produce and sell big joint implants in India.
• In June 2022, the EU granted ATRO Medical a grant of €2.5 million to develop a meniscus prosthesis. The € 2.5 million award will be used for worldwide clinical investigations, health economic assessments, and expediting pre-clinical testing of the meniscus prosthesis.

Company Revenue

In March 2025, full-year financial results were announced by Medacta Group SA. The adjusted EBITDA margin showed constant currency of 28.0%, reflecting an excellent performance by the company. Moreover, the 19.4% to Euro 160.2 million growth was reported for adjusted EBITDA. Euro 590.6 million, up 16.2% in c.c.2, was noted for FY 2024 revenue. Additionally, a distribution of CHF 0.69 per share with a rise of 25.5% yoy was proposed by the board of directors. Furthermore, for 2025, the company is expecting a revenue growth between the range of 13% to 15% in c.c. and a 27% rise in the adjusted EBITDA margin, where the Parcus acquisition will be included.

In February 2025, the Q4 2024 Earnings Call was released by Zimmer Biomet Holdings Inc. (ZBH). A 4.3% revenue growth, that is $2.23 billion, was observed along with a constant currency of 4.9%. 5% growth, which was reported for constant currency revenue for the fourth quarter of 2024. The prior year showed the adjusted earnings per share (EPS) $2.20, where this year showed a growth upto $2.31. The free cash flow and adjusted operating margin for this year were reported to be $1.055 billion and 30.8%, respectively. Moreover, the knees, hips, and S.E.T. net sales reported a growth of 5.6%, 4%, and 8.4%. Additionally, for the fourth quarter of 2024, the adjusted tax rate was noted to be 17.5%.

Moreover, as per the 2025 financial guidance, 3% to 5% constant currency revenue growth, along with $8.15 to $8.35 adjusted EPS, was observed. $526 million was reported to be cash and cash equivalents at the end of the quarter.

Latest Announcement by Industry Leaders

Corey Perine, Chief Operating Officer at Maxx Orthopedics, commented that the IDE application approval for the Freedom Total Knee System with PEEK Optima Femoral Component is a monumental achievement and the culmination of more than a decade of collaboration between Maxx Orthopedics and Invibio. He is satisfied to see the next step in the development of this innovation reach fruition.

In July 2025, Chief of the Sports Medicine Institute at the Hospital for Special Surgery in New York City, MD, Riley J. Williams III, said that their osteochondral allografts defined their career. In certain cases, the biology fails and is no longer a good choice for a patient, and it's too early for any kind of joint replacement. Thus, an implant that resurfaces the joint, offering a lasting, durable, and predictable solution, adhering to the joint preservation principles, will be provided by them for bridging the gap between the joint replacement and biologic options.

Recent Developments

• In June 2024, Meril, a medical equipment firm located in Gujarat, introduced MISSO, an indigenously designed surgical robotic system that will let surgeons perform knee replacement procedures in real time.
• In June 2024, the FDA granted DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, 510(k) approval for the clinical use of the VELYSTM Robotic-Assisted Solution in Unicompartmental Knee Arthroplasty (UKA), according to a statement released by Johnson & Johnson MedTech.

Partner with our experts to explore the Knee Replacement Prosthesis Market at sales@towardshealthcare.com